IMV’s clinical-stage cancer programs are evaluating the use of our lead candidate, Maveropepimut-S and oral intermittent low dose of cyclophosphamide (an immunomodulatory agent) with and without Pembrolizumab, Merck’s checkpoint inhibitor.
We’re proud to address hard-to-treat cancers and areas of unmet medical needs through our clinical trials, bringing new hope to patients.
This phase 2 clinical trial is evaluating Maveropepimut-S in an open-label safety and efficacy study in ovarian cancer patients. These patients have advanced platinum-sensitive and resistant ovarian cancer, with a sum of baseline target lesions per response evaluation criteria in solid tumors less than five centimeters.
Phase 2 clinical trial to evaluate Maveropepimut-S in combination with the checkpoint inhibitor Keytruda® (pembrolizumab) from Merck. These are patients with recurrent, platinum-resistant and sensitive , and patients with measurable or recurrent diffuse large B cell lymphoma (DLBCL).
A phase 2 basket trial is underway in combination with Merck’s Keytruda® (pembrolizumab). The patients have select advanced or recurrent solid tumors in bladder, liver (hepatocellular carcinoma), ovarian, or non-small-cell lung (NSCLC) cancers, as well as tumors positive for the microsatellite instability-high (MSI-H) biomarker.
This completed phase 1, First in Humans, randomized (2:2:1) observer blind, controlled, dose ranging, multi-arm parallel-group clinical trial in healthy persons 50 to 64 years of age to assess the safety and immunogenicity of two dose levels of a novel vaccine formulation DPX-RSV(A) consisting of a synthetic Respiratory Syncytial Virus SHe antigen combined with a novel adjuvant DepoVaxTM, compared to the antigen combined with the commonly used adjuvant Aluminum hydroxide, and to a saline placebo control.View Trial
In some circumstances, IMV is able to offer access to our investigational drugs (drugs not approved by regulatory agencies) to patients who cannot access the treatment through clinical trials. To assess the possibility for you to receive one of our investigational treatments, the request must come from your treating physician. Your physician knows your medical history and current situation and will be in the best position to complete the request. Therefore, we invite you to discuss your specific details with your physician who can help determine if this might be an appropriate option for you. If so, your physician may send a request for IMV’s special access program (SAP) at email@example.com. The request will then be evaluated by IMV, and your physician will let you know if you are eligible or not.
For our DPX-COVID-19 vaccine candidate: clinical studies evaluating IMV’s vaccine candidate against COVID-19 are conducted independently by investigator physicians: Dr. Michael Libman at the McGill University Health Center in Montreal and Dr. Joanne Langley of the Canadian Center of Vaccinology at Dalhousie University in Halifax. Details of the study and contact details of the investigators are at the bottom of this web page:Learn More